WG
GYRE icon

Winton Group’s Gyre Therapeutics GYRE Stock Holding History

Winton Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,467
Closed -$220K – 690
2024
Q2 		$220K Buy
+18,467
New +$253K 0.01% 524
2020
Q4 		– Sell
-1,710
Closed -$55K – 1395
2020
Q3 		$55K Buy
+1,710
New +$66.9K ﹤0.01% 1440
2020
Q1 		– Sell
-5,678
Closed -$290K – 1456
2019
Q4 		$290K Buy
5,678
+4,248
+297% +$178K ﹤0.01% 1370
2019
Q3 		$53K Buy
+1,430
New +$77.1K ﹤0.01% 1495

Other funds holding GYRE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AACP
Advantage Alpha Capital Partners San Francisco, California $332M AUM 12.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Winton Group's GYRE Position: Q3 2024 in Review

Winton Group sold out of Gyre Therapeutics (GYRE) in Q3 2024, closing a stake of 18,467 shares — an estimated $220K sold.

Winton Group first reported a position in GYRE in Q3 2019 and held it in 4 quarters. The position peaked at $290K in Q4 2019. 37 funds tracked by Wall St. Rank hold GYRE as of Q3 2024.

  • Winton Group reported no remaining Gyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Winton Group sold 18,467 Gyre Therapeutics shares in Q3 2024, an estimated $220K.
  • Winton Group first reported a position in Gyre Therapeutics in Q3 2019 and held it in 4 quarters.
  • Winton Group's Gyre Therapeutics position peaked at $290K in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2024.

Based on Winton Group's 13F filing for Q3 2024, filed 12 Nov 2024.